Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Carcinoma, Renal Cell 4Prostatic Neoplasms 2Bile Duct Neoplasms 2Vulvar Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Gallbladder Neoplasms 1Disease Progression 1Clear-cell metastatic renal cell carcinoma 1Cholangiocarcinoma 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1

Interventions

pembrolizumab 4aldesleukin 3Cisplatin 3lenvatinib 2Surveys and Questionnaires 2Specimen Handling 2Paclitaxel 2Nivolumab 2Magnetic Resonance Spectroscopy 2Adoptive Transfer 2zimberelimab 1trastuzumab deruxtecan 1tivozanib 1liposomal doxorubicin 1fludarabine phosphate 1fludarabine 1entinostat 1dostarlimab 1cemiplimab 1bintrafusp alfa protein, human 1belzutifan 1atezolizumab 1Therapeutic Touch 1Taxes 1Standard of Care 1Sonazoid 1Respiratory Function Tests 1Radiotherapy 1Radiation 1Prochlorperazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vulvar Neoplasms × tivozanib × 1 year × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡